Trastuzumab Deruxtecan Is Active in HER2 Low-Expressing Breast Cancer
The novel HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki demonstrated promising antitumor activity in patients with heavily pretreated, HER2 low-expressing advanced or metastatic breast cancer.
Source: OncLive
Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) Reports Fourth Quarter and Full Year 2020




